Losartan Safety Signals and FDA Actions

How Losartan Works: Mechanism of Action

Losartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from triggering vasoconstriction, aldosterone secretion, and sympathetic nervous system activation. This is the same renin-angiotensin-aldosterone system (RAAS) targeted by ACE inhibitors, but ARBs like losartan act downstream at the receptor level rather than blocking the converting enzyme 1.

The drug is a prodrug. After oral absorption, hepatic cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4) convert losartan to its active metabolite EXP-3174, which has 10 to 40 times greater affinity for the AT1 receptor than the parent compound 2. This metabolic step matters for safety because CYP2C9 poor metabolizers (roughly 1 to 3% of Caucasian populations) generate less EXP-3174, potentially reducing efficacy rather than increasing toxicity. The half-life of losartan itself is approximately 2 hours, while EXP-3174 persists for 6 to 9 hours, supporting once-daily dosing at 25 to 100 mg 1.

Unlike ACE inhibitors, losartan does not inhibit bradykinin degradation. That distinction explains its lower incidence of dry cough (roughly 3% vs. up to 15% with ACE inhibitors) and its reduced but not zero risk of angioedema 3.

FDA Approval History and Labeled Indications

Losartan received FDA approval on April 14, 1995, making it the first ARB available in the United States 4. Merck marketed it as Cozaar. Three labeled indications now exist: hypertension (adults and pediatric patients 6 years and older), reduction of stroke risk in hypertensive patients with left ventricular hypertrophy, and diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes.

The stroke indication came from the LIFE trial, published in The Lancet in 2002 (N=9,193), which randomized hypertensive patients with ECG-documented left ventricular hypertrophy to losartan-based or atenolol-based therapy 5. The losartan group showed a 13% relative risk reduction in the primary composite endpoint of cardiovascular death, stroke, and myocardial infarction (p=0.021). Stroke alone was reduced by 25% (p=0.001). That trial changed prescribing patterns and earned losartan its second indication.

The nephroprotection indication followed the RENAAL trial (N=1,513), which demonstrated a 16% reduction in the composite endpoint of doubling of serum creatinine, end-stage renal disease, or death among type 2 diabetics with nephropathy 6.

The Black-Box Warning: Fetal Toxicity

Losartan carries the FDA's most serious warning category. The black-box label states: "When pregnancy is detected, discontinue losartan potassium as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus" 4.

This warning applies to all ARBs and ACE inhibitors. Exposure during the second and third trimesters has been linked to renal tubular dysgenesis, oligohydramnios, fetal skull hypoplasia, pulmonary hypoplasia, and neonatal death 7. A retrospective cohort analysis published in the New England Journal of Medicine found that first-trimester ACE inhibitor exposure was associated with a risk ratio of 2.71 for major congenital malformations (95% CI 1.72 to 4.27), though whether this extends identically to ARBs remains debated 7.

The clinical instruction is unambiguous. Women of childbearing potential starting losartan should receive pregnancy counseling, and the drug should be stopped immediately upon confirmed pregnancy.

NDMA Contamination: The 2018-2020 Recall Crisis

Between July 2018 and late 2020, the FDA issued a cascade of recalls affecting ARBs contaminated with nitrosamine impurities, primarily N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). These are probable human carcinogens classified by the International Agency for Research on Cancer as Group 2A 8.

The contamination was initially discovered in valsartan manufactured by Zhejiang Huahai Pharmaceutical but quickly expanded to losartan and irbesartan products. By March 2019, the FDA had identified nitrosamine impurities in losartan tablets from multiple manufacturers, including Torrent Pharmaceuticals, Hetero Labs, Macleods Pharmaceuticals, and Legacy Pharmaceutical Packaging 9.

The root cause traced back to changes in active pharmaceutical ingredient (API) synthesis that introduced nitrosamine-forming conditions. Certain solvents and catalysts used during tetrazole ring formation created the conditions for NDMA generation. The FDA determined that some batches contained NDMA levels exceeding the acceptable daily intake limit of 96 nanograms per day 9.

In September 2019, the FDA released interim limits for nitrosamine impurities in ARBs and established mandatory testing requirements for API manufacturers. Dr. Janet Woodcock, then Director of the FDA's Center for Drug Evaluation and Research, stated: "We have been working tirelessly to get to the bottom of how these impurities formed, and we're taking steps to ensure this doesn't happen again" 9.

By February 2021, the FDA finalized guidance requiring all pharmaceutical manufacturers to assess and control nitrosamine impurity risk across their product portfolios, not limited to ARBs 10. This regulatory shift represented one of the largest quality-control overhauls in generic pharmaceutical manufacturing in the past two decades.

Patients who took recalled lots were advised not to stop losartan abruptly (given the cardiovascular risk of untreated hypertension) but to obtain replacement supplies from unaffected batches. The estimated excess cancer risk from the contamination was characterized as low: approximately 1 additional case per 8,000 patients exposed to the highest NDMA levels over four years of daily use 9.

Hyperkalemia: A Predictable Class Effect

All RAAS inhibitors raise serum potassium by reducing aldosterone-mediated renal potassium excretion. In losartan clinical trials, hyperkalemia (serum K+ >5.5 mEq/L) occurred in 1.5% of patients 4. The RENAAL trial reported a higher rate: 7.5% in the losartan group versus 4.0% in placebo, with a 0.1 mEq/L mean increase in potassium over the study period 6.

Risk factors compound. Patients with chronic kidney disease (eGFR <30 mL/min/1.73 m²), those taking potassium-sparing diuretics, potassium supplements, or NSAIDs, and patients with diabetes are at highest risk. The American Heart Association recommends monitoring serum potassium within 2 to 4 weeks of initiating or uptitrating any RAAS inhibitor, with repeat testing at least annually thereafter 11.

Combining losartan with an ACE inhibitor (dual RAAS blockade) was tested in the ONTARGET trial (N=25,620) and found to increase hyperkalemia, hypotension, and renal dysfunction without improving cardiovascular outcomes 12. The ACC/AHA hypertension guidelines now advise against dual RAAS blockade outside of select heart failure scenarios managed by specialists.

Hepatotoxicity: Rare but Documented

Post-marketing surveillance has identified rare cases of hepatotoxicity associated with losartan. The National Institutes of Health LiverTox database documents a pattern of mixed hepatocellular-cholestatic injury typically presenting 1 to 6 months after initiation 13.

Most cases resolved after discontinuation. A small number progressed to acute liver failure requiring transplantation. The mechanism appears to be idiosyncratic rather than dose-dependent, and cross-reactivity with other ARBs has been reported in some cases, though rechallenge with a different ARB has also been tolerated 13.

The prescribing label does not require routine liver function monitoring. Clinicians should consider losartan as a potential cause when evaluating new-onset transaminase elevations in patients taking the drug, particularly when other hepatotoxins have been excluded.

Angioedema and Hypersensitivity

Angioedema occurs with ARBs at a lower rate than with ACE inhibitors, but it does occur. A meta-analysis published in the Annals of Internal Medicine estimated the incidence of ARB-associated angioedema at 0.11% compared to 0.30% for ACE inhibitors 3.

The FDA label for losartan notes that patients with a history of ACE inhibitor-related angioedema may still develop angioedema with an ARB. Cross-reactivity is not universal. A systematic review found that approximately 2 to 17% of patients with ACE inhibitor angioedema developed recurrent episodes when switched to an ARB 14. Black patients face higher angioedema risk across both drug classes, a finding consistent across LIFE, ONTARGET, and multiple post-marketing databases 5.

Angioedema involving the airway is a medical emergency. Patients should be counseled to seek immediate care for swelling of the face, lips, tongue, or throat.

Renal Effects and Acute Kidney Injury

Losartan reduces intraglomerular pressure by dilating the efferent arteriole. This is the mechanism behind its nephroprotective effect in diabetic nephropathy but also the reason it can precipitate acute kidney injury (AKI) in volume-depleted patients. The prescribing information warns that renal function should be monitored periodically, especially in patients whose renal function depends on RAAS activity (bilateral renal artery stenosis, severe heart failure, volume depletion) 4.

A population-based cohort study published in the BMJ found that triple therapy with an RAAS inhibitor, a diuretic, and an NSAID increased the rate of AKI by 31% compared to RAAS inhibitor monotherapy (rate ratio 1.31, 95% CI 1.12 to 1.53) 15. The practical takeaway: clinicians prescribing losartan should review concurrent medications, and patients should be advised to hold the drug during acute illness with volume losses (vomiting, diarrhea, or poor oral intake).

Post-Marketing Surveillance: What FAERS Data Show

The FDA Adverse Event Reporting System (FAERS) has accumulated tens of thousands of reports for losartan since approval. The most frequently reported adverse events include dizziness, hyperkalemia, hypotension, cough, renal impairment, and fatigue 9. FAERS data are hypothesis-generating rather than confirmatory, as reporting rates do not equal incidence rates, and the system captures voluntary reports subject to significant bias.

No new black-box warnings have been added since the original fetal toxicity warning. The 2018 to 2020 nitrosamine episode did not result in changes to losartan's approved labeling but instead triggered manufacturing-level regulatory changes across the entire generic pharmaceutical industry.

The Endocrine Society's 2020 clinical practice guideline on primary aldosteronism noted that losartan and other ARBs should be discontinued (when clinically safe) before confirmatory testing for aldosterone-producing adenomas, as these drugs can confound the aldosterone-to-renin ratio 16.

Current Regulatory Status and Prescribing Considerations

Losartan remains FDA-approved with no restrictions beyond its labeled warnings. Generic versions are available from over a dozen manufacturers, and the drug appears on the WHO Model List of Essential Medicines 4. Current FDA-required labeling includes: the black-box fetal toxicity warning, warnings for hypotension (especially in volume-depleted patients), hyperkalemia, and impaired renal function.

The 2024 FDA guidance on nitrosamine risk assessment requires all losartan API suppliers to test for NDMA, NDEA, and other nitrosamine species and to demonstrate levels below the acceptable intake limit before releasing batches for tablet manufacturing 10.

Dr. Robert Califf, FDA Commissioner, has described the nitrosamine episode as "a wake-up call for global pharmaceutical supply chain oversight" and noted that the agency now maintains a standing testing program for nitrosamine impurities across multiple drug classes 9.

For prescribers initiating losartan today, the safety checklist is straightforward: confirm no pregnancy or pregnancy intent, check baseline renal function and potassium, review concurrent medications for triple-threat AKI risk (RAAS inhibitor + diuretic + NSAID), and recheck electrolytes and creatinine within 2 to 4 weeks of starting therapy.